A CRA expert provided input to the Canadian Competition Bureau in its evaluation of the proposed merger of two branded pharmaceutical manufacturers. CRA’s team considered the ability and incentive of the merging parties to increase the price of a branded pharmaceutical following the merger. Aspects of this consideration included setting out the features of list and net pricing of branded drugs in the Canadian pharmaceutical marketplace, and the various constraints and factors that bear on those prices.
CRA Competition economists contribute to article-by-article commentary on the EU Foreign Subsidies Regulation
It gives the European Commission far-reaching powers to scrutinize financial contributions from non-EU governments to companies active in the EU, including in...